NovaBay Pharmaceuticals (NBY) Competitors $0.61 0.00 (-0.16%) As of 03/28/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock NBY vs. IXHL, AFMD, MRKR, SPRB, MTVA, HCWB, IPA, CTXR, ATHA, and BMRAShould you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include Incannex Healthcare (IXHL), Affimed (AFMD), Marker Therapeutics (MRKR), Spruce Biosciences (SPRB), MetaVia (MTVA), HCW Biologics (HCWB), ImmunoPrecise Antibodies (IPA), Citius Pharmaceuticals (CTXR), Athira Pharma (ATHA), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. NovaBay Pharmaceuticals vs. Incannex Healthcare Affimed Marker Therapeutics Spruce Biosciences MetaVia HCW Biologics ImmunoPrecise Antibodies Citius Pharmaceuticals Athira Pharma Biomerica Incannex Healthcare (NASDAQ:IXHL) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment. Do insiders and institutionals hold more shares of IXHL or NBY? 0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 26.5% of Incannex Healthcare shares are held by insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, IXHL or NBY? NovaBay Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncannex Healthcare$98K129.39-$18.46M-$1.39-0.51NovaBay Pharmaceuticals$13.84M0.26-$9.64M-$53.72-0.01 Do analysts rate IXHL or NBY? NovaBay Pharmaceuticals has a consensus price target of $0.85, indicating a potential upside of 39.80%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NovaBay Pharmaceuticals is more favorable than Incannex Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IXHL or NBY? In the previous week, Incannex Healthcare and Incannex Healthcare both had 1 articles in the media. Incannex Healthcare's average media sentiment score of 1.89 beat NovaBay Pharmaceuticals' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Overall Sentiment Incannex Healthcare Very Positive NovaBay Pharmaceuticals Neutral Which has more volatility & risk, IXHL or NBY? Incannex Healthcare has a beta of 7.49, suggesting that its share price is 649% more volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Is IXHL or NBY more profitable? Incannex Healthcare has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Incannex Healthcare's return on equity of -289.30% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Incannex HealthcareN/A -289.30% -154.96% NovaBay Pharmaceuticals -102.72%-7,293.78%-158.41% Does the MarketBeat Community prefer IXHL or NBY? NovaBay Pharmaceuticals received 1 more outperform votes than Incannex Healthcare when rated by MarketBeat users. CompanyUnderperformOutperformIncannex HealthcareN/AN/ANovaBay PharmaceuticalsOutperform Votes11.64%Underperform Votes6098.36% SummaryIncannex Healthcare and NovaBay Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get NovaBay Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBY vs. The Competition Export to ExcelMetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.54M$6.90B$5.63B$19.40BDividend YieldN/A2.76%5.33%3.76%P/E Ratio-0.017.2623.5533.04Price / Sales0.26218.61388.1926.59Price / CashN/A65.6738.1717.55Price / Book0.146.386.894.53Net Income-$9.64M$142.34M$3.20B$1.02B7 Day Performance-6.17%-5.15%-3.06%-1.30%1 Month Performance0.50%-7.55%1.51%-4.04%1 Year Performance-83.41%-11.06%9.37%2.55% NovaBay Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBYNovaBay Pharmaceuticals1.5232 of 5 stars$0.61-0.2%$0.85+39.8%-83.4%$3.54M$13.84M-0.0130Analyst ForecastIXHLIncannex Healthcare0.9333 of 5 stars$0.80-3.5%N/A-80.2%$14.29M$98,000.00-0.583Positive NewsAFMDAffimed4.4169 of 5 stars$0.87-1.8%$13.50+1,448.2%-85.3%$14.04M$877,000.000.00200Short Interest ↓News CoverageMRKRMarker Therapeutics3.9377 of 5 stars$1.28+2.4%$13.50+954.7%-70.5%$13.71M$3.31M0.0060Short Interest ↑News CoverageGap UpSPRBSpruce Biosciences3.1816 of 5 stars$0.33-2.0%$2.50+657.8%-62.5%$13.63M$7.10M-0.3520Upcoming EarningsShort Interest ↓Positive NewsGap DownMTVAMetaVia2.1906 of 5 stars$1.58+1.9%$12.00+659.5%N/A$13.61MN/A0.0010HCWBHCW Biologics1.4213 of 5 stars$0.30-1.2%N/A-82.9%$13.36M$3.50M-0.3040Earnings ReportNews CoverageGap UpIPAImmunoPrecise Antibodies2.2907 of 5 stars$0.43+1.6%$5.00+1,062.8%-74.2%$13.36M$24.07M-0.5580Earnings ReportShort Interest ↑News CoverageCTXRCitius Pharmaceuticals3.2961 of 5 stars$1.55+2.0%$54.50+3,416.1%-93.1%$13.32MN/A0.0020Positive NewsATHAAthira Pharma2.5166 of 5 stars$0.34+2.4%$13.83+3,968.6%-88.9%$13.27MN/A-0.1240Positive NewsBMRABiomerica0.9714 of 5 stars$0.71+3.6%N/A-30.1%$13.02M$5.58M-2.0960Short Interest ↓News CoveragePositive News Remove Ads Related Companies and Tools Related Companies IXHL Alternatives AFMD Alternatives MRKR Alternatives SPRB Alternatives MTVA Alternatives HCWB Alternatives IPA Alternatives CTXR Alternatives ATHA Alternatives BMRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NBY) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew Pick (93% history of rising by May 8)We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the p...InvestorPlace | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
